预约演示 免费注册 新闻 最新 研发 交易 投融资 政策 透视 全球快讯 12 小时之前 · PRNewswire ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention Oct. 12, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States. Seasonal vaccination remains central to influenza prevention. However, changes in circulating influenza viruses and va 疫苗 临床结果 临床申请 免疫疗法 17 小时之前 · dignifytherapeutics.com Dignify Therapeutics Presents Preclinical Data on DTI-117 in Neurogenic Bowel Dysfunction at ACG 2026 DTI-117 induced defecation within minutes of intramuscular injection in conscious minipigs, with responder rates rising with dose, and confirmed in a crossover study Pharmacokinetic profile of rapid absorption and fast clearance, with a mean terminal half-life of approximately 3 to 4 minutes, is consistent with a short-acting effect DTI-117 is being evaluated in a NIH-funded randomized, double-blind, placebo-controlled Phase 1 single-ascending-dose study October 13, 2026 – Dignify Therapeutics 高管变更 17 小时之前 · BioSpace Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity -- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity -- Oct. 13, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of 上市批准 临床结果 孤儿药 17 小时之前 · BioSpace Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo. No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants. A rapid one-step titration to the target dose of 400 mg QD in Cohort 5 was equally well tolerated with all TEAEs being mild, with nausea and vomiting each reported in only 12.5% of participants, supporting further evaluation of “no titrati 临床结果 17 小时之前 · PRNewswire Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company advances toward clinical development and attracts Chris Brearley, M.D., as Chief Medical Officer Oct. 14, 2026 -- Carnyx Therapeutics Ltd. (" Carnyx" or the " Company"), a preclinical-stage biopharmaceutical company developing first-in-class molecular therapeutics for sleep and retinitis pigmentosa, today unveiled CNYX-005, its lead oral sleep candidate, alongside preclinical findings showing increased total sleep ti 临床结果 19 小时之前 · BioSpace Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery A spin-out focused on AI-enabled decoding of the deliverome Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease Round co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital Undecimal Bio (“Undecimal”), a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribe siRNA 19 小时之前 · PRNewswire Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases Oct. 13, 2026 -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for obesity and metabolic diseases. Inhibition of ALK7 by directly targeting adipocytes has 引进/卖出 2026-10-13 · PRNewswire Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE) Oct. 12, 2026 -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting 并购 高管变更 2026-10-13 · PRNewswire Sharp Biomedical Closes Pre-Seed Funding Led by Gener8tor to Advance Outpatient Spine Procedures for Early-to-Mid-Stage Chronic Pain Oct. 12, 2026 -- Sharp Biomedical, a medical device company pioneering accessible, safe, and manual procedures for outpatient pain clinics, announced today the successful closing of its pre-seed funding round. The round was led by gener8tor 1889, a North Dakota venture capital fund, with participation from several physician angel investors. Dan Newman, Founder and CEO The new capital will fully fund the development and testing pathway necessary to bring Sharp Biomedical's first purpose-built too 2026-10-13 · Business Wire Chipscreen Biosciences Announced NMPA Approval of IND for CS43158, an AML Candidate Discovered via the AI-enabled Chemical Genomics Platform Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences” or the “Company”)(SSE: 688321) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for CS43158 tablets, a new molecular entity for the treatment of acute myeloid leukemia (AML), discovered through the company’s AI-enabled Chemical Genomics Platform. CS43158 is a multikinase inhibitor with global patent protection, independently developed by Chipscr 临床申请 < 1 2 3 4 5 >> 10 > 提出任何生物医药研究问题 让每一步生物医药决策都精准制胜 基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现 热门报告 2025 ESMO解读报告 智慧芽生物医药 2025年赛诺菲交易收购策略分析 智慧芽生物医药 GLP1R 小分子激动剂专利 fast follow 策略 智慧芽生物医药 立即开始免费试用! 智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。 开始免费试用 立即接入生物医药数据包 智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。 准备好接入了吗？ 立即获取API秘钥→